DEVELOPMENT ENGINE

                      Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

                      Interact with the Regeneron Pipeline

                      Select Therapeutic Area(s):
                      Select Phase(s):
                      Select Collaborator(s):

                      Displaying item(s)

                      Clear Filters

                      Regeneron Pipeline: Phase 1 Medicines Regeneron Pipeline: Phase 1 Medicines
                      • CEMIPLIMAB*
                        PD-1 Antibody Cancer
                      • REGN3767
                        LAG-3 Antibody Solid tumors, advanced hematologic malignancies
                      • REGN1979
                        CD20 X CD3 Antibody B-cell malignancies
                      • REGN4018*
                        MUC16 X CD3 Antibody Platinum-resistant ovarian cancer
                      • REGN5458*
                        BCMA X CD3 Antibody Multiple myeloma
                      • REGN5459*
                        BCMA X CD3 Antibody Multiple myeloma
                      • REGN5678
                        PSMA X CD28 Antibody Prostate cancer
                      • REGN5093
                        MET X MET Antibody MET-altered advanced non-small cell lung cancer (NSCLC)
                      • REGN5713-5714-5715
                        Bet v 1 Antibodies Birch Allergy
                      Regeneron Pipeline: Phase 2 Medicines Regeneron Pipeline: Phase 2 Medicines
                      • AFLIBERCEPT
                        VEGF-Trap High-dose (8mg) for wet age-related macular degeneration (AMD)
                      • CEMIPLIMAB*
                        PD-1 Antibody Basal cell carcinoma (BCC), metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC
                      • REGN1979
                        CD20 X CD3 Antibody B-cell non-Hodgkin lymphoma
                      • SARILUMAB*
                        IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
                      • DUPILUMAB*
                        IL-4R Antibody Grass allergy, peanut allergy
                      • REGN1908-1909
                        Fel d 1 Antibodies Cat allergy
                      • REGN3500*
                        IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD)
                      • REGN5069
                        GFRα3 Antibody Osteoarthritis pain of the knee
                      • GARETOSMAB
                        Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)
                      • EVINACUMAB
                        ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia
                      • POZELIMAB
                        C5 Antibody Paroxysmal nocturnal hemoglobinuria, CD-55 deficient protein-losing enteropathy
                      • REGN4461
                        LEPR Antibody Generalized lipodystrophy
                      Regeneron Pipeline: Phase 3 Medicines Regeneron Pipeline: Phase 3 Medicines
                      • AFLIBERCEPT
                        VEGF-Trap Retinopathy of prematurity (ROP)
                      • CEMIPLIMAB*
                        PD-1 Antibody non-small cell lung cancer (NSCLC), cervical cancer, adjuvant cutaneous squamous cell carcinoma (CSCC)
                      • ALIROCUMAB
                        PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatric patients, heterozygous familial hypercholesterolemia in pediatric patients
                      • EVINACUMAB
                        ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)
                      • DUPILUMAB*
                        IL-4R Antibody Atopic dermatitis in pediatric patients 6 mo.–11 y.o., asthma in pediatric patients 6-11 y.o., eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria
                      • SARILUMAB*
                        IL-6R Antibody Hospitalized "critical" COVID-19 patients, polymyalgia rheumatica, giant cell arteritis
                      • REGN-EB3
                        Ebola Virus Antibodies Ebola virus infection
                      • FASINUMAB?
                        NGF Antibody Osteoarthritis pain of the knee or hip

                      No results found, please adjust your filter selection and try again.

                      * In collaboration with Sanofi

                      ? In collaboration with Teva and Mitsubishi Tanabe

                      This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.